Guiyang Xintian Pharmaceutical Co.,Ltd. (SHE:002873)
China
· Delayed Price · Currency is CNY 10.09
+0.27 (2.75%)
Apr 30, 2026, 2:05 PM CST
SHE:002873 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 748.82 | 856.87 | 953.26 | 1,087 | 968.7 | Upgrade
|
| Other Revenue | 0.9 | 0.67 | 0.73 | 0.88 | 1.15 | Upgrade
|
| Revenue | 749.72 | 857.55 | 953.98 | 1,088 | 969.84 | Upgrade
|
| Revenue Growth (YoY) | -12.57% | -10.11% | -12.29% | 12.15% | 29.15% | Upgrade
|
| Cost of Revenue | 216.67 | 230.72 | 219.39 | 247.65 | 201.16 | Upgrade
|
| Gross Profit | 533.05 | 626.83 | 734.59 | 840.02 | 768.69 | Upgrade
|
| Selling, General & Admin | 456.71 | 513.64 | 589.02 | 673.99 | 606.18 | Upgrade
|
| Research & Development | 42.55 | 40.47 | 38.13 | 21.58 | 20.38 | Upgrade
|
| Other Operating Expenses | 12.31 | 12 | 10.54 | 13.17 | 13.81 | Upgrade
|
| Operating Expenses | 510.19 | 568.72 | 637.42 | 709.27 | 642.1 | Upgrade
|
| Operating Income | 22.86 | 58.11 | 97.17 | 130.75 | 126.58 | Upgrade
|
| Interest Expense | -17.76 | -17.57 | -11.8 | -10.67 | -16.6 | Upgrade
|
| Interest & Investment Income | 0.42 | 0.67 | 0.92 | 0.73 | 1.37 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | 0 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 0.31 | -0.05 | 1.92 | -5.41 | -2.93 | Upgrade
|
| EBT Excluding Unusual Items | 5.83 | 41.16 | 88.21 | 115.39 | 108.42 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.02 | 0.02 | -0.72 | -0.4 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.78 | 18.9 | - | -0.02 | -0.1 | Upgrade
|
| Asset Writedown | -0.16 | -0.71 | -0.07 | -0.12 | -0.37 | Upgrade
|
| Other Unusual Items | 4.9 | 1.38 | 5 | 6.48 | 8.69 | Upgrade
|
| Pretax Income | 9.77 | 60.76 | 92.42 | 121.34 | 116.65 | Upgrade
|
| Income Tax Expense | 0.66 | 8.43 | 11.55 | 9.83 | 16.04 | Upgrade
|
| Earnings From Continuing Operations | 9.11 | 52.32 | 80.87 | 111.52 | 100.61 | Upgrade
|
| Net Income | 9.11 | 52.32 | 80.87 | 111.52 | 100.61 | Upgrade
|
| Net Income to Common | 9.11 | 52.32 | 80.87 | 111.52 | 100.61 | Upgrade
|
| Net Income Growth | -82.59% | -35.30% | -27.48% | 10.85% | 35.76% | Upgrade
|
| Shares Outstanding (Basic) | 235 | 220 | 232 | 232 | 227 | Upgrade
|
| Shares Outstanding (Diluted) | 235 | 220 | 245 | 244 | 245 | Upgrade
|
| Shares Change (YoY) | 6.87% | -9.91% | 0.41% | -0.41% | 1.34% | Upgrade
|
| EPS (Basic) | 0.04 | 0.24 | 0.35 | 0.48 | 0.44 | Upgrade
|
| EPS (Diluted) | 0.04 | 0.24 | 0.33 | 0.46 | 0.41 | Upgrade
|
| EPS Growth | -83.70% | -28.18% | -27.78% | 11.30% | 33.96% | Upgrade
|
| Free Cash Flow | 32.14 | 26.68 | -23.92 | -53.38 | 18.61 | Upgrade
|
| Free Cash Flow Per Share | 0.14 | 0.12 | -0.10 | -0.22 | 0.08 | Upgrade
|
| Dividend Per Share | 0.030 | 0.100 | 0.070 | 0.100 | 0.086 | Upgrade
|
| Dividend Growth | -70.00% | 42.86% | -30.00% | 16.69% | 40.03% | Upgrade
|
| Gross Margin | 71.10% | 73.10% | 77.00% | 77.23% | 79.26% | Upgrade
|
| Operating Margin | 3.05% | 6.78% | 10.19% | 12.02% | 13.05% | Upgrade
|
| Profit Margin | 1.21% | 6.10% | 8.48% | 10.25% | 10.37% | Upgrade
|
| Free Cash Flow Margin | 4.29% | 3.11% | -2.51% | -4.91% | 1.92% | Upgrade
|
| EBITDA | 55.74 | 90.4 | 117.51 | 155.38 | 148.33 | Upgrade
|
| EBITDA Margin | 7.43% | 10.54% | 12.32% | 14.29% | 15.29% | Upgrade
|
| D&A For EBITDA | 32.88 | 32.29 | 20.34 | 24.64 | 21.74 | Upgrade
|
| EBIT | 22.86 | 58.11 | 97.17 | 130.75 | 126.58 | Upgrade
|
| EBIT Margin | 3.05% | 6.78% | 10.19% | 12.02% | 13.05% | Upgrade
|
| Effective Tax Rate | 6.73% | 13.88% | 12.49% | 8.10% | 13.75% | Upgrade
|
| Revenue as Reported | 749.72 | 857.55 | 953.98 | 1,088 | 969.84 | Upgrade
|
| Advertising Expenses | 13.09 | 16.57 | 43.46 | 43.15 | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.